Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.58 |
| ▸ | TK1 | P04183 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 9-Methylguanine SCHEMBL27339404 | 0.98 | XDH (0.57) | XDHTK1PNPUSP2TSHR | |
| 9-Methylguanine SCHEMBL27638388 | 0.90 | XDH (0.52) | XDHTK1PNPUSP2TSHR | |
| 9-Methylguanine SCHEMBL28106048 | 0.83 | XDH (0.47) | XDHTK1PNPUSP2TSHR | |
| SCHEMBL986800 | 0.82 | XDH (0.60) | XDHTK1PNPUSP2TSHR | |
| SCHEMBL29286376 | 0.81 | TK1 (0.76) | TK1PNPUSP2TSHREDNRA | |
| SCHEMBL41787 | 0.81 | XDH (0.59) | XDHTK1PNPUSP2TSHR | |
| SCHEMBL27667185 | 0.81 | XDH (0.63) | XDHTK1PNPUSP2TSHR | |
| SCHEMBL9910656 | 0.81 | XDH (0.42) | XDHTK1PNPHPRT1KMT2A | |
| SCHEMBL15005119 | 0.81 | XDH (0.59) | XDHTK1PNPUSP2TSHR | |
| SCHEMBL24374442 | 0.80 | XDH (0.47) | XDHTK1PNPHPRT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6169 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099790-A1 | DEVICE USING ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-05-15 | — | — | WO | claimed |
| US-20260131157-A1 | METHODS OF USING ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-05-14 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| EP-4452256-B1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2025-12-10 | — | — | EP | claimed |
| US-12473663-B2 | Compositions and methods for immune repertoiresequencing | Life Technologies Corporation (US) | 2025-11-18 | — | — | US | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | claimed |
| EP-4267763-B1 | COMPOSITIONS AND METHODS FOR HIGHLY SENSITIVE DETECTION OF TARGET SEQUENCES IN MULTIPLEX REACTIONS | LIFE TECHNOLOGIES CORP (US) | 2025-07-23 | — | — | EP | claimed |
| US-12350318-B2 | Combination therapy to treat brain cancer | INOVIO PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | claimed |
| WO-2000058329-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | GOLDSBOROUGH, ANDREW (FR) | 2000-10-05 | — | — | WO | claimed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1998042723-A9 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | — | 1999-03-04 | — | — | WO | claimed |
| EP-0540693-B1 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING $i(IN VITRO) NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | HOFFMANN LA ROCHE (CH) | 1999-01-20 | — | — | EP | claimed |
| US-5703224-A | Antiviral c-nucleoside derivatives | NIPPON SHINYAKU CO. LTD. (JP) | 1997-12-30 | — | — | US | claimed |
| EP-0733630-A1 | NUCLEOSIDE DERIVATIVE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | claimed |
| EP-0625985-A1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES. | UNIV MIAMI (US) | 1994-11-30 | — | — | EP | claimed |
| WO-1993011146-A1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES | UNIVERSITY OF MIAMI (US) | 1993-06-10 | — | — | WO | claimed |
| EP-0540693-A1 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING $i(IN VITRO) NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001814-A2 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING IN VITRO NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | F. HOFFMANN-LA-ROCHE AG (CH) | 1992-02-06 | — | — | WO | claimed |